発作(Seizures):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Seizures - Pipeline Review, H2 2014
◆商品コード:GMDHC5803IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における発作(Seizures)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・発作(Seizures)の概要
・発作(Seizures)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・発作(Seizures)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・発作(Seizures)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・発作(Seizures)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Seizures – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Seizures – Pipeline Review, H2 2014’, provides an overview of the Seizures’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seizures
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Seizures and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Seizures products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Seizures pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Seizures
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Seizures Overview 8
Therapeutics Development 9
Pipeline Products for Seizures – Overview 9
Pipeline Products for Seizures – Comparative Analysis 10
Seizures – Therapeutics under Development by Companies 11
Seizures – Therapeutics under Investigation by Universities/Institutes 13
Seizures – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Seizures – Products under Development by Companies 17
Seizures – Products under Investigation by Universities/Institutes 18
Seizures – Companies Involved in Therapeutics Development 19
Acorda Therapeutics, Inc. 19
Advicenne Pharma 20
Alexza Pharmaceuticals, Inc. 21
Concert Pharmaceuticals, Inc. 22
Neurelis, Inc. 23
Novartis AG 24
Pfizer Inc. 25
Sage Therapeutics 26
Ultragenyx Pharmaceutical Inc. 27
Upsher-Smith Laboratories, Inc. 28
Seizures – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
ADV-6208 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
alprazolam – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
C-10068 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CCG-63802 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CHEC-9 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
diazepam – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
diazepam – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diazepam – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
everolimus – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
midazolam hydrochloride – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SAGE-217 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
UX-007 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Seizures – Recent Pipeline Updates 61
Seizures – Dormant Projects 71
Seizures – Discontinued Products 72
Seizures – Product Development Milestones 73
Featured News & Press Releases 73
Sep 02, 2014: SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs 73
Nov 01, 2013: Systematic Review Finds Intranasal Midazolam Comparable To Intravenous Or Rectal Administration Of Diazepam For Treatment Of Acute Seizure Emergencies In Pediatric Patients 73
Jun 24, 2013: Upsher-Smith Labs Announces Patient Enrollment In Open-label Safety Study Of USL261 For Rescue Treatment Of Seizure Clusters In Epilepsy 74
May 06, 2013: Alexza Pharma To Present Data On AZ-002 At Antiepileptic Drug And Device Trials Conference 75
Mar 19, 2013: Upsher-Smith Labs Presents Favorable Phase I Data For USL261 At 65th Annual Meeting Of AAN 75
Nov 26, 2012: Upsher-Smith Labs Presents Clinical Data On Midazolam At American Epilepsy Society Annual Meeting 76
Apr 26, 2012: Upsher-Smith Provides Update On Phase III Seizure Clusters Study 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

[List of Tables]
Number of Products under Development for Seizures, H2 2014 9
Number of Products under Development for Seizures - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Seizures - Pipeline by Acorda Therapeutics, Inc., H2 2014 19
Seizures - Pipeline by Advicenne Pharma, H2 2014 20
Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H2 2014 21
Seizures - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 22
Seizures - Pipeline by Neurelis, Inc., H2 2014 23
Seizures - Pipeline by Novartis AG, H2 2014 24
Seizures - Pipeline by Pfizer Inc., H2 2014 25
Seizures - Pipeline by Sage Therapeutics, H2 2014 26
Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2014 27
Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Seizures Therapeutics - Recent Pipeline Updates, H2 2014 61
Seizures - Dormant Projects, H2 2014 71
Seizures - Discontinued Products, H2 2014 72

[List of Figures]
Number of Products under Development for Seizures, H2 2014 9
Number of Products under Development for Seizures - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Top 10 Targets, H2 2014 30
Number of Products by Stage and Top 10 Targets, H2 2014 31
Number of Products by Top 10 Mechanism of Actions, H2 2014 32
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 33
Number of Products by Top 10 Routes of Administration, H2 2014 34
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 35
Number of Products by Top 10 Molecule Types, H2 2014 36
Number of Products by Stage and Top 10 Molecule Types, H2 2014 37

【掲載企業】

Acorda Therapeutics, Inc.
Advicenne Pharma
Alexza Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
Neurelis, Inc.
Novartis AG
Pfizer Inc.
Sage Therapeutics
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[発作(Seizures):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆